Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy
Michael Wang(St. Joseph Health System), Simon Rule(AstraZeneca (United Kingdom)), Britte Kranenburg(Janssen (Netherlands)), Peter Martin(Northwestern University), Radhakrishnan Ramchandren(The Christie NHS Foundation Trust), Ranjana H. Advani(Stanford Medicine), Irit Avivi(Tel Aviv Sourasky Medical Center), Rakesh Popat(University College London Hospitals NHS Foundation Trust), William Deraedt(Janssen (Belgium)), André Goy(Hackensack University Medical Center), Zhilong Yuan(Janssen (United States)), Julia Alexeeva(Federal Almazov North-West Medical Research Centre), Sen Hong Zhuang(Janssen (United States)), Netanel A. Horowitz(Rambam Health Care Campus), Aleksandra Rizo(Geron (United States)), Steven Le Gouill(Inserm)
Cited by 34
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k